ChemoCentryx, Inc. (NASDAQ: CCXI) is a biopharmaceutical company that specializes in creating orally administered new medicines that inhibit chemo-attractant receptors – the engines of cell migration in disease. The company focuses exclusively on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. By altering the cellular microenvironment in diseases of inflammation, autoimmunity, and cancer, the company intends to generate better treatment outcomes. For more information, visit the company’s website at www.chemocentryx.com.
ChemoCentryx (CCXI) Presents at Rodman & Renshaw Conference
Previous Article
Next Article
Search Articles
Latest Articles
- FAVO Capital Inc. (FAVO): When Private Credit Meets Real Estate Collateralization
- AI and the Copper Conundrum: How Trilogy Metals Inc. (NYSE American: TMQ) (TSX: TMQ) Fits into the Supply Equation
- Silvercorp Metals Inc. (NYSE-A/TSX: SVM) El Domo Environmental License Upheld as Ecuador’s Constitutional Court Dismisses Final Challenge
- NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Seeks FDA Ban on Toxic Ketamine Preservative
- MissionIRNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Closes $6.9 Million Public Offering Including Full Over-Allotment Option